CPRX Stock Overview
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.
Catalyst Pharmaceuticals, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$17.27|
|52 Week High||US$18.39|
|52 Week Low||US$5.24|
|1 Month Change||23.53%|
|3 Month Change||25.60%|
|1 Year Change||151.75%|
|3 Year Change||269.81%|
|5 Year Change||331.75%|
|Change since IPO||183.12%|
Recent News & Updates
Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?Nov 11
With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Is InterestingNov 03
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Low P/E No Reason For ExcitementMar 30
Does Catalyst Pharmaceuticals (NASDAQ:CPRX) Deserve A Spot On Your Watchlist?Mar 09
We're Not Counting On Catalyst Pharmaceuticals (NASDAQ:CPRX) To Sustain Its Statutory ProfitabilityFeb 11
Could The Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Ownership Structure Tell Us Something Useful?Jan 21
Is Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock's Recent Performance A Reflection Of Its Financial Health?Dec 27
Our View On Catalyst Pharmaceuticals' (NASDAQ:CPRX) CEO PayDec 06
|CPRX||US Biotechs||US Market|
Return vs Industry: CPRX exceeded the US Biotechs industry which returned -7.4% over the past year.
Return vs Market: CPRX exceeded the US Market which returned -14.9% over the past year.
|CPRX Average Weekly Movement||8.5%|
|Biotechs Industry Average Movement||11.2%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: CPRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: CPRX's weekly volatility (9%) has been stable over the past year.
About the Company
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies.
Catalyst Pharmaceuticals, Inc. Fundamentals Summary
|CPRX fundamental statistics|
Is CPRX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CPRX income statement (TTM)|
|Cost of Revenue||US$47.60m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.64|
|Net Profit Margin||34.90%|
How did CPRX perform over the long term?See historical performance and comparison